Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

NCT04530461 | Unknown

• 1 other identifier: UR17DN02-002
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease, Rheumatoid arthritis and Spondyloarthritis

Conditions

SARS-CoV Infection; Systemic Disease; Systemic Lupus Erythematosus; Sjogren's Syndrome; Sarcoidosis; Inflammatory Myopathy; Behçet Disease; Rheumatoid Arthritis; Spondyloarthritis

Outcome Measures

Primary Outcomes (1)

• Serological Profile

  Number of patients with positive serological test of SARS Cov2

  Inclusion

Interventions

Serological test DIAGNOSTIC_TEST

Positive serological test of SARS Cov2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with one of the following conditions: systemic lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory myopathies, spondyloarthritis, sarcoidosis and Behçet's disease.

You may qualify if:

• Age over 18 years old
• One of the following conditions: systemic lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory myopathies, spondyloarthritis, sarcoidosis and Behçet's disease.
• Informed consent obtained and signed

You may not qualify if:

• Refusal to repeat blood sampling if the first one was badly performed
• Informed consent not obained

Sponsors & Collaborators

• faida agili: lead
• UR17DN02 : Autoimmune Diseases Research Unit: collaborator

Study Sites (1)

Military Hospital of Tunis

Tunis, Tunisia

RECRUITING

MeSH Terms

Conditions

Severe Acute Respiratory Syndrome; Lupus Erythematosus, Systemic; Sjogren's Syndrome; Sarcoidosis; Myositis; Behcet Syndrome; Arthritis, Rheumatoid; Spondylarthritis

Interventions

Serologic Tests

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Xerostomia; Salivary Gland Diseases; Mouth Diseases; Stomatognathic Diseases; Dry Eye Syndromes; Lacrimal Apparatus Diseases; Eye Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Muscular Diseases; Neuromuscular Diseases; Nervous System Diseases; Uveitis, Anterior; Panuveitis; Uveitis; Uveal Diseases; Vasculitis; Vascular Diseases; Cardiovascular Diseases; Hereditary Autoinflammatory Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Skin Diseases; Skin Diseases, Vascular; Spondylitis; Spinal Diseases; Bone Diseases

Intervention Hierarchy (Ancestors)

Immunologic Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Immunologic Techniques

Study Officials

• Faida Ajili, MD

  Military Hospital of Tunis

  STUDY CHAIR

Central Study Contacts

Faida Ajili, MD

CONTACT

+21698631188; faida1977@yahoo.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director of Autoimmune Diseases Research Unit (UR17DN02) and Professor in internal medicine departement. Sponsor and Principal Investigator

Study Record Dates

• First Submitted: August 26, 2020
• First Posted: August 28, 2020
• Study Start: June 1, 2020
• Primary Completion: November 30, 2020
• Study Completion: January 31, 2021
• Last Updated: September 22, 2020

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)